December 2024

December's Top Stories: Deaths lead to major recalls | IVL a top priority | Mass layoffs | Heart surgeon discusses robotic AVR ()
Our favorite Q&A interviews of the year: Device recalls | Robotic AVR | Tricuspid breakthroughs | Much more! ()
Patient deaths lead to device recalls | Cardiologists perform first-in-human heart procedures | AFib & TAVR ()
CMS proposes Medicare coverage for TTVR | Hydra TAVR valve gains key approval | Palliative care for stroke survivors ()
IVL a top priority | Patient deaths lead to major recalls | First-in-human implants | FDA clears heart monitor | Doctor attacked ()
Drug shortage ends after 2 years | Exploring CCTA's value | Cardiologist attacked | The future of AI & vascular surgery ()
Cryoablation catheters recalled | Merck spends big on new drug | SAVR bests TAVR | FDA expands total artificial heart study ()
Historic pacemaker implants | IVL tech a top priority | CEO resigns over conduct allegations | FDA clears new heart monitor ()
SCAI president reviews big achievements in 2024 | Boston Scientific recalls more than 200,000 pacemakers ()
New ACC recommendations on managing acute myocarditis | How to slash readmissions after surgery | AFib & TAVR ()
Week in Review: Device concerns put patients at risk | Mass layoffs | TAVR/PCI vs. SAVR/CABG | New AI for echo ()
'A significant step forward' | FDA head shares concerns | Heart pumps approved for younger patients | AI for echo ()
Heart surgeons discuss historic procedure | The benefits of AI-powered CCTA evaluations | Safety concerns may have backfired ()
Cardiothoracic surgery linked to limited diversity, uneven salaries | Improved TAVR outcomes in patients with concomitant MS ()
TAVR & PCI vs. SAVR & CABG | First device of its kind granted key FDA exemption | Depression impacts TAVR outcomes ()
Vulnerable heart patients are still treatable | Insulet awarded $452M in damages | Medical device company cuts 70% of staff ()
Week in Review: The first heart surgery of its kind | An exclusive look at robotic AVR | FDA approves new drug | PPM after TAVR ()
Interventional cardiology's first Match Day | Cleerly raises $106M | The costs of AI-powered ECG screening | Depression & CVD ()
Pioneer heart surgeon discusses robotic AVR | Plant-based protein reduces heart risks | Philips & Mayo launch AI partnership ()
The first robotic heart surgery of its kind | Off-label TAVR for native AR | Clopidogrel vs. aspirin for different risk groups ()
IVL safe, effective in patients with calcified nodules | Key TAVR data out of London ()
November's Top Stories: Surgical devices recalled | CMS increases CCTA payments | Robotic AVR vs. TAVR | Surgeons make history ()
PPM after TAVR in patients with small annuli | FDA approves new fast-acting heart drug | Mediterranean diet helps older adults ()